An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions

Chung Feng Huang, Chao Hung Hung, Pin Nan Cheng, Ming Jong Bair, Yi Hsiang Huang, Jia Horng Kao, Shih Jer Hsu, Pei Lun Lee, Jyh Jou Chen, Rong Nan Chien, Cheng Yuan Peng, Chun Yen Lin, Tsai Yuan Hsieh, Chun Han Cheng, Chia Yen Dai, Jee Fu Huang, Wan Long Chuang, Ming Lung Yu

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Fingerprint

Dive into the research topics of 'An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions'. Together they form a unique fingerprint.

Medicine & Life Sciences